Table 2.
Univariable | Multivariable | |||||
---|---|---|---|---|---|---|
HR | 95% CI | p value | HR | 95% CI | p value | |
mRNA expression (n = 510) | ||||||
YY1 high vs. low | 1.35 | 1.03–1.78 | 0.030 | 1.26 | 0.94–1.68 | 0.127 |
YY1 z score | 1.08 | 0.99–1.19 | 0.068 | 1.05 | 0.94–1.18 | 0.365 |
CP2 high vs. low | 1.11 | 0.84–1.45 | 0.465 | 1.24 | 0.94–1.65 | 0.133 |
CP2 z score | 1.07 | 0.95–1.20 | 0.262 | 1.14 | 1.00–1.29 | 0.049 |
YY1CP2 score | 1.55 | 1.16–2.05 | 0.003 | 1.60 | 1.19–2.16 | 0.002 |
mRNA expression—interaction analysis (n = 510) | ||||||
YY1 + (ref. YY1 − CP2 −) | 0.97 | 0.66–1.43 | 0.892 | 0.89 | 0.59–1.34 | 0.570 |
CP2 + (ref. YY1 − CP2 −) | 0.74 | 0.48–1.13 | 0.165 | 0.82 | 0.52–1.29 | 0.398 |
YY1 + CP2 + | 1.96 | 1.12–3.43 | 0.018 | 1.99 | 1.11–3.58 | 0.021 |
CNV (n = 510) | ||||||
YY1 high vs. low | 1.33 | 1.02–1.75 | 0.036 | 1.19 | 0.89–1.59 | 0.230 |
YY1 values | 1.20 | 0.63–2.31 | 0.582 | 1.10 | 0.57–2.12 | 0.778 |
CP2 high vs. low | 0.83 | 0.63–1.09 | 0.185 | 0.90 | 0.68–1.20 | 0.479 |
CP2 values | 0.88 | 0.30–2.58 | 0.813 | 1.16 | 0.37–3.58 | 0.803 |
YY1CP2 score | 1.10 | 0.81–1.49 | 0.555 | 1.07 | 0.78–1.48 | 0.669 |
Protein expression (n = 102) | ||||||
YY1 | 0.66 | 0.31–1.40 | 0.281 | 0.63 | 0.28–1.44 | 0.275 |
CP2 | 0.90 | 0.52–1.57 | 0.712 | 1.05 | 0.59–1.88 | 0.861 |
YY1CP2 score | 0.60 | 0.27–1.33 | 0.207 | 0.66 | 0.29–1.51 | 0.320 |
p value below 0.05 was considered significant and highlighted (bold)
mRNA levels were analyzed for their expression level (high vs. low) and per change of z score unit. Multivariable analysis was adjusted for staging, HPV status and smoker status. For mRNA expression, the pair-wise interaction for high expressions of YY1 and CP2 was calculated. A p value below 0.05 was considered significant and highlighted (bold).
HR, hazard ratio, CI confidence interval, ref. reference, + high expression, − low expression